v3.22.2.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 172,567 $ 199,091
Short-term available-for-sale investments 74,462 32,463
Accounts receivable, less allowance for doubtful accounts of $2,568 and $1,229, respectively 194,548 145,385
Inventories 141,123 116,748
Other current assets 22,856 16,919
Total current assets 605,556 510,606
Property and equipment, net 223,242 207,907
Right of use asset 65,556 73,834
Goodwill 822,101 843,067
Intangible assets, net 531,522 615,968
Other assets 46,828 11,575
Total assets 2,294,805 2,262,957
Current liabilities:    
Trade accounts payable 33,865 29,384
Salaries, wages and related accruals 61,953 51,294
Accrued expenses 17,886 15,282
Contract liabilities 23,406 18,995
Income taxes payable 13,237 5,336
Operating lease liabilities - current 11,928 11,602
Contingent consideration payable   4,000
Current portion of long-term debt obligations 12,500 12,500
Other current liabilities 1,243 3,891
Total current liabilities 176,018 152,284
Deferred income taxes 98,994 93,125
Long-term debt obligations 243,410 328,827
Long-term contingent consideration payable 5,000 25,400
Operating lease liabilities 58,133 67,625
Other long-term liabilities 12,239 24,462
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,160,000 and 38,955,484, respectively 392 390
Additional paid-in capital 653,657 534,411
Retained earnings 1,122,921 1,085,461
Accumulated other comprehensive loss (75,200) (57,291)
Total Bio-Techne's shareholders' equity 1,701,770 1,562,971
Noncontrolling interest (759) 8,263
Total shareholders' equity 1,701,011 1,571,234
Total liabilities and shareholders' equity $ 2,294,805 $ 2,262,957

Source